Different liposomal amphotericin B formulations for visceral leishmaniasis–Author's reply
نویسندگان
چکیده
منابع مشابه
Comparison between liposomal formulations of amphotericin B.
Given the clinical success of commercial amphotericin B lipid products, investigators have begun making generic formulations of liposomal amphotericin B. Generic medicines are an attractive approach to help decrease the cost and accessibility to healthcare, provided that appropriate studies are performed to ensure bioequivalence with the parent product. This is of particular concern for liposom...
متن کاملLiposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
Caryn Bern, Jill Adler-Moore, Juan Berenguer, Marleen Boelaert, Margriet den Boer, Robert N. Davidson, Concepcion Figueras, Luigi Gradoni, Dimitris A. Kafetzis, Koert Ritmeijer, Eric Rosenthal, Catherine Royce, Rosario Russo, Shyam Sundar, and Jorge Alvar Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; California State Polytechnic University, Pomona...
متن کاملAmphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
Visceral leishmaniasis (VL), which is endemic in the Indian subcontinent (42,623 reported cases/year of which 34,918 were in India), the Mediterranian region (875 cases/year), East Africa (8,569 cases/year), and Brazil (3,481 cases/year) has undergone a revolution in chemotherapy in the last 15 years. Treatment had been with the classical agents pentavalent antimony and amphotericin B deoxychol...
متن کاملAntimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had become unresponsive to (or had relapsed after) treatment with appropriate doses of liposomal amphotericin B. Under close follow-up, full courses of pentavalent antimony were administered without life-threatening adverse events and resulted in rapid and sustained clinical and parasitological cure.
متن کاملLiposomal amphotericin B in the treatment of visceral leishmaniasis.
A case of visceral leishmaniasis unresponsive to several course of treatment with standard drugs, was successfully cured by a 21 day course (50 mg/day) of liposomal amphotericin B (AmBisome, Vestar Inc.). The efficacy of the AmBisome formulation is supported by experimental studies on Leishmania donovani infected BALB/c mice where ED50 values of AmBisome and conventional amphotericin B were 0.1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Global Health
سال: 2014
ISSN: 2214-109X
DOI: 10.1016/s2214-109x(14)70270-0